PHARMABCINE INC
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 2024-04-23 07:25
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors 2024-01-24 10:01
PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome 2023-11-23 10:31
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data 2023-11-09 21:00
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD 2023-07-26 20:00
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD 2023-05-23 20:00
PharmAbcine to participate in "BIO International Convention 2023" 2023-05-08 20:00
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab) 2022-12-12 21:00
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week 2022-12-08 21:00
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 2022-10-17 20:00
PharmAbcine to Participate in BIO-Europe 2022 2022-09-26 20:00
PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention 2022-05-11 20:00
PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study 2022-04-26 20:30
PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology 2022-04-26 20:00
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022 2022-04-11 20:00
RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics 2022-03-21 20:00
NuclixBio Announces a Collaborative Research Agreement with PharmAbcine 2022-03-14 20:00
PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial 2022-02-25 21:00
PharmAbcine Announces Patent Grant in Australia for Its Anti-VISTA Antibody 2021-10-19 20:00
PharmAbcine to Participate in BIO-Europe 2021 2021-09-20 20:00
1 2 3